Advertisement

Topics

Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report [Report Updated: 30092017] Prices from USD $175

06:50 EDT 25 Oct 2017 | BioPortfolio Reports

Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report


Summary


Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.


Key Highlights


Hikma Pharmaceuticals Hikma or 'the company' is engaged in the development, manufacture and marketing of generic and inlicensed pharmaceutical products. The company primarily operates in the Middle East and North Africa MENA, the US and Europe. It is headquartered in London, the UK and employs around 7,248 people.


Scope


Detailed information on Hikma Pharmaceuticals PLC required for business and competitor intelligence needs

A study of the major internal and external factors affecting Hikma Pharmaceuticals PLC in the form of a SWOT analysis

An indepth view of the business model of Hikma Pharmaceuticals PLC including a breakdown and examination of key business segments

Intelligence on Hikma Pharmaceuticals PLC's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about Hikma Pharmaceuticals PLC, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends


Reasons to buy


Gain understanding of Hikma Pharmaceuticals PLC and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Hikma Pharmaceuticals PLC as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Hikma Pharmaceuticals PLC's business structure, strategy and prospects.

Original Article: Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report [Report Updated: 30092017] Prices from USD $175

NEXT ARTICLE

More From BioPortfolio on "Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report [Report Updated: 30092017] Prices from USD $175"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...